Prothrombin
Thrombin (EC 3.4.21.5, fibrinogenase, thrombase, thrombofort, topical, thrombin-C, tropostasin, activated blood-coagulation
prothrombin , blood-coagulation factor IIa, factor IIa, E thrombin, beta-thrombin, gamma-thrombin) may be a serine protease, an enzyme that, in humans, is encoded by the F2 gene.
Prothrombin (coagulation factor II) is proteolytically cleaved to make thrombin within the clotting process. Thrombin successively acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, also as catalyzing many other coagulation-related reactions. Thrombin is produced by the enzymatic cleavage of two sites on
prothrombin by activated prothrombinase (Xa). The activity of factor Xa is greatly enhanced by binding to activated proaccelerin (Va), termed the prothrombinase complex.
Prothrombin is produced within the liver and is co-translationally modified during a vitamin K-dependent reaction that converts 10-12 glutamic acids within the N terminus of the molecule to gamma-carboxyglutamic acid (Gla). Within the presence of calcium, the Gla residues promote the binding of
prothrombin to phospholipid bilayers. Deficiency of vitamin K or
administration of the anticoagulant warfarin inhibits the assembly of gamma-carboxyglutamic acid residues, slowing the activation of the coagulation cascade.
Prothrombin G20210A isn't usually amid other factor
mutations (i.e., the foremost common is proaccelerin Leiden). The
gene could also be inherited heterozygous (1 pair), or far more rarely, homozygous (2 pairs), and isn't associated with gender or
blood group . Homozygous
mutations increase the danger of thrombosis quite heterozygous mutations, but the relative increased risk isn't well documented.
High Impact List of Articles
-
Immune senescence and cardiomyopathy associated with obesity
Motoaki Sano*, Kohsuke Shirakawa, Tsunehisa Yamamoto
Mini Review: Interventional Cardiology
-
Immune senescence and cardiomyopathy associated with obesity
Motoaki Sano*, Kohsuke Shirakawa, Tsunehisa Yamamoto
Mini Review: Interventional Cardiology
-
Reversible SA Nodal Dysfunction
Kumar D*, Pawar A, Sabnis G, Shah H, Lanewar C, Kerkar P, More D
Case Report: Interventional Cardiology
-
Reversible SA Nodal Dysfunction
Kumar D*, Pawar A, Sabnis G, Shah H, Lanewar C, Kerkar P, More D
Case Report: Interventional Cardiology
-
The use of subintimal pathways to facilitate chronic total occlusion procedural success
JW Strange
Commentary: Interventional Cardiology
-
The use of subintimal pathways to facilitate chronic total occlusion procedural success
JW Strange
Commentary: Interventional Cardiology
-
Minimally invasive left atrial appendage ligation in an animal model
SC Bertog, DH Steinberg, N Wunderlich, J Franke & H Sievert
Short Article: Interventional Cardiology
-
Minimally invasive left atrial appendage ligation in an animal model
SC Bertog, DH Steinberg, N Wunderlich, J Franke & H Sievert
Short Article: Interventional Cardiology
-
Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions
M Koutouzis & L Grip
Review Article: Interventional Cardiology
-
Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions
M Koutouzis & L Grip
Review Article: Interventional Cardiology
Relevant Topics in Clinical